NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Price Target & More

$12.94 -0.22 (-1.67 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$13.16
Today's Range$12.88 - $13.26
52-Week Range$10.00 - $19.51
Volume56,064 shs
Average Volume202,300 shs
Market Capitalization$339.44 million
P/E Ratio-9.48
Dividend YieldN/A
Beta-0.32

About Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global logoOxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Debt-to-Equity Ratio0.34%
Current Ratio5.37%
Quick Ratio4.92%

Price-To-Earnings

Trailing P/E Ratio-9.48
Forward P/E Ratio-13.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$103.08 million
Price / Sales3.25
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book3.78

Profitability

EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-31.90%
Return on Equity-42.38%
Return on Assets-23.65%

Miscellaneous

Employees457
Outstanding Shares25,870,000

How to Become a New Pot Stock Millionaire

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global (NASDAQ:OXFD) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.02. The company had revenue of $25.03 million for the quarter, compared to analyst estimates of $25.12 million. Oxford Immunotec Global had a negative net margin of 31.90% and a negative return on equity of 42.38%. The firm's revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.22) earnings per share. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Oxford Immunotec Global.

What price target have analysts set for OXFD?

4 brokers have issued 1 year target prices for Oxford Immunotec Global's stock. Their forecasts range from $15.00 to $21.00. On average, they expect Oxford Immunotec Global's share price to reach $18.75 in the next twelve months. View Analyst Ratings for Oxford Immunotec Global.

What are Wall Street analysts saying about Oxford Immunotec Global stock?

Here are some recent quotes from research analysts about Oxford Immunotec Global stock:
  • 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (3/13/2018)
  • 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)

Who are some of Oxford Immunotec Global's key competitors?

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Richard A. Sandberg, Independent Chairman of the Board (Age 74)
  • Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director (Age 42)
  • Richard M. Altieri, Chief Financial Officer (Age 57)
  • Stefan C. Linn, Chief Operating Officer (Age 51)
  • Peter Edwardson Ph.D., Senior Vice President & Head of Blood Screening (Age 52)
  • Elizabeth M. Keiley, Vice President, General Counsel (Age 51)
  • Richard J. Wenstrup M.D., Chief Medical Officer (Age 65)
  • Ronald A. Andrews Jr., Director (Age 57)
  • Patrick J. Balthrop Sr., Director (Age 60)
  • Mark Klausner, Director

Has Oxford Immunotec Global been receiving favorable news coverage?

News headlines about OXFD stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 45.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $12.94.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $339.44 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (OXFD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oxford Immunotec Global (NASDAQ:OXFD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Oxford Immunotec Global in the last 12 months. Their average twelve-month price target is $18.75, suggesting that the stock has a possible upside of 44.90%. The high price target for OXFD is $21.00 and the low price target for OXFD is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.75$18.75$19.75$22.00
Price Target Upside: 44.90% upside62.90% upside32.64% upside27.54% upside

Oxford Immunotec Global (NASDAQ:OXFD) Consensus Price Target History

Price Target History for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ:OXFD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018CowenReiterated RatingBuy$15.00HighView Rating Details
12/18/2017BTIG ResearchSet Price TargetBuy$21.00MediumView Rating Details
11/1/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/31/2017Piper JaffrayLower Price TargetOverweight$26.00 -> $19.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Oxford Immunotec Global (NASDAQ:OXFD) Earnings History and Estimates Chart

Earnings by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ:OXFD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.99)
2019 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.46)($0.46)($0.46)
Q2 20181($0.20)($0.20)($0.20)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.23)($0.23)($0.23)
Q1 20191($0.39)($0.39)($0.39)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.05)($0.05)($0.05)
Q4 20191($0.19)($0.19)($0.19)

Oxford Immunotec Global (NASDAQ OXFD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.40)N/AView Earnings Details
2/27/2018Q4 2017($0.36)($0.34)$25.12 million$25.03 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.26)($0.24)$30.11 million$30.43 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.32)$25.05 million$26.10 millionViewListenView Earnings Details
5/2/20173/31/2017($0.35)($0.36)$21.17 million$21.51 millionViewListenView Earnings Details
3/1/201712/31/2016($0.39)($0.22)$23.06 million$23.71 millionViewListenView Earnings Details
11/1/2016Q316($0.33)($0.18)$24.79 million$26.10 millionViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.29)$18.10 million$19.20 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.32)$16.96 million$17.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.28)($0.29)$16.34 million$16.00 millionViewN/AView Earnings Details
11/3/2015Q315($0.25)($0.20)$17.31 million$17.90 millionViewN/AView Earnings Details
8/4/2015Q215($0.34)($0.33)$14.04 million$14.30 millionViewN/AView Earnings Details
5/5/2015Q115($0.33)($0.31)$13.35 million$13.80 millionViewN/AView Earnings Details
3/3/2015Q414($0.44)($0.39)$11.93 million$12.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.38)($0.35)$12.85 million$13.30 millionViewN/AView Earnings Details
8/5/2014Q214($0.20)($0.36)$11.39 million$11.80 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.18)$11.64 million$12.30 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.38)$9.28 million$10.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Oxford Immunotec Global (NASDAQ:OXFD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oxford Immunotec Global (NASDAQ OXFD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 93.31%
Insider Trading History for Oxford Immunotec Global (NASDAQ:OXFD)
Insider Trading History for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ OXFD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Richard A SandbergDirectorSell3,000$12.01$36,030.00View SEC Filing  
11/1/2017Richard A SandbergDirectorSell3,000$13.35$40,050.0017,778View SEC Filing  
10/2/2017Peter Wrighton-SmithCEOSell55,000$16.78$922,900.00View SEC Filing  
9/1/2017Richard A SandbergDirectorSell3,000$15.82$47,460.0018,000View SEC Filing  
8/15/2017Peter EdwardsonCOOSell9,739$16.14$157,187.4692,905View SEC Filing  
8/7/2017Peter EdwardsonCOOSell22,371$17.70$395,966.70102,644View SEC Filing  
7/6/2017Peter Wrighton-SmithCEOSell27,168$15.94$433,057.92488,836View SEC Filing  
7/5/2017Peter Wrighton-SmithCEOSell32,832$16.58$544,354.56478,106View SEC Filing  
6/28/2017Peter Wrighton-SmithCEOSell30,000$16.06$481,800.00491,668View SEC Filing  
6/15/2017Elizabeth M KeileyVPSell4,085$15.01$61,315.8525,393View SEC Filing  
5/15/2017Peter EdwardsonCOOSell10,000$14.66$146,600.00125,015View SEC Filing  
5/10/2017Richard A SandbergDirectorSell3,000$14.40$43,200.0020,174View SEC Filing  
5/9/2017Jeff R SchroederInsiderSell40,000$14.14$565,600.00149,544View SEC Filing  
4/3/2017Peter Wrighton-SmithCEOSell30,000$15.43$462,900.00491,668View SEC Filing  
4/3/2017Richard A SandbergDirectorSell3,000$15.47$46,410.0017,174View SEC Filing  
3/20/2017Elizabeth M KeileyVPSell3,000$16.05$48,150.0025,429View SEC Filing  
2/6/2017Peter Wrighton-SmithCEOSell25,000$13.36$334,000.00463,495View SEC Filing  
12/16/2016Peter Wrighton-SmithCEOSell7,052$15.07$106,273.64450,366View SEC Filing  
12/5/2016Peter Wrighton-SmithCEOSell1,140$15.00$17,100.00444,454View SEC Filing  
12/2/2016Peter Wrighton-SmithCEOSell61,808$15.00$927,120.00504,122View SEC Filing  
11/8/2016Richard A SandbergDirectorSell12,000$14.17$170,040.0031,774View SEC Filing  
11/18/2015Richard A. SandbergDirectorSell5,000$13.48$67,400.0032,174View SEC Filing  
11/17/2015Richard A. SandbergDirectorSell5,000$13.00$65,000.0037,174View SEC Filing  
6/16/2015Lifesciences I L.P. ClarusMajor ShareholderSell41,230$14.30$589,589.00View SEC Filing  
6/15/2015Lifesciences I L.P. ClarusMajor ShareholderSell1,529$14.27$21,818.83View SEC Filing  
6/12/2015Lifesciences I L.P. ClarusMajor ShareholderSell31,598$14.27$450,903.46View SEC Filing  
6/10/2015Lifesciences I L.P. ClarusMajor ShareholderSell24,649$14.28$351,987.72View SEC Filing  
6/9/2015Lifesciences I L.P. ClarusMajor ShareholderSell13,000$14.26$185,380.00View SEC Filing  
6/8/2015Lifesciences I L.P. ClarusMajor ShareholderSell2,662$14.25$37,933.50View SEC Filing  
6/3/2015Lifesciences I L.P. ClarusMajor ShareholderSell36,474$14.29$521,213.46View SEC Filing  
6/1/2015Richard A SandbergDirectorSell3,000$14.14$42,420.00View SEC Filing  
3/23/2015Lifesciences I L.P. ClarusMajor ShareholderSell53,415$14.49$773,983.35View SEC Filing  
3/19/2015Lifesciences I L.P. ClarusMajor ShareholderSell154,319$14.65$2,260,773.35View SEC Filing  
1/14/2015Richard A SandbergDirectorSell3,000$14.00$42,000.00View SEC Filing  
12/5/2014Patricia RandallDirectorSell5,000$12.06$60,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oxford Immunotec Global (NASDAQ OXFD) News Headlines

Source:
DateHeadline
Oxford Immunotec Global (OXFD) and Its Peers Financial SurveyOxford Immunotec Global (OXFD) and Its Peers Financial Survey
www.americanbankingnews.com - April 19 at 5:23 PM
Q1 2018 EPS Estimates for Oxford Immunotec Global Lowered by Analyst (OXFD)Q1 2018 EPS Estimates for Oxford Immunotec Global Lowered by Analyst (OXFD)
www.americanbankingnews.com - April 19 at 6:50 AM
Oxford Immunotec Global (OXFD) Expected to Announce Quarterly Sales of $20.91 MillionOxford Immunotec Global (OXFD) Expected to Announce Quarterly Sales of $20.91 Million
www.americanbankingnews.com - April 18 at 4:16 AM
Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018
finance.yahoo.com - April 17 at 9:51 AM
-$0.40 EPS Expected for Oxford Immunotec Global (OXFD) This Quarter-$0.40 EPS Expected for Oxford Immunotec Global (OXFD) This Quarter
www.americanbankingnews.com - April 16 at 7:13 AM
Oxford Immunotec Global (OXFD) & Its Peers Head-To-Head ComparisonOxford Immunotec Global (OXFD) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 7:21 PM
Oxford Immunotec Global (OXFD) Earns Buy Rating from Piper JaffrayOxford Immunotec Global (OXFD) Earns Buy Rating from Piper Jaffray
www.americanbankingnews.com - April 13 at 6:01 PM
Oxford Immunotec Global (OXFD) Earns Buy Rating from CowenOxford Immunotec Global (OXFD) Earns Buy Rating from Cowen
www.americanbankingnews.com - April 13 at 6:01 PM
Head to Head Analysis: Oxford Immunotec Global (OXFD) vs. Its CompetitorsHead to Head Analysis: Oxford Immunotec Global (OXFD) vs. Its Competitors
www.americanbankingnews.com - April 11 at 8:47 AM
Critical Contrast: Oxford Immunotec Global (OXFD) versus Its CompetitorsCritical Contrast: Oxford Immunotec Global (OXFD) versus Its Competitors
www.americanbankingnews.com - April 10 at 9:15 AM
Oxford Immunotec Global (OXFD) Receives Consensus Recommendation of "Buy" from AnalystsOxford Immunotec Global (OXFD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 10 at 1:41 AM
Trinity Biotech (TRIB) versus Oxford Immunotec Global (OXFD) Financial ReviewTrinity Biotech (TRIB) versus Oxford Immunotec Global (OXFD) Financial Review
www.americanbankingnews.com - April 8 at 9:19 PM
Head to Head Comparison: Oxford Immunotec Global (OXFD) vs. Its RivalsHead to Head Comparison: Oxford Immunotec Global (OXFD) vs. Its Rivals
www.americanbankingnews.com - April 7 at 11:15 PM
Oxford Immunotec Global (OXFD) Rating Reiterated by Robert W. BairdOxford Immunotec Global (OXFD) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM
Vermillion (VRML) & Oxford Immunotec Global (OXFD) Head to Head ComparisonVermillion (VRML) & Oxford Immunotec Global (OXFD) Head to Head Comparison
www.americanbankingnews.com - April 2 at 3:06 AM
Oxford Immunotec Global (OXFD) Expected to Post Quarterly Sales of $21.69 MillionOxford Immunotec Global (OXFD) Expected to Post Quarterly Sales of $21.69 Million
www.americanbankingnews.com - April 1 at 4:20 AM
Zacks: Analysts Expect Oxford Immunotec Global (OXFD) Will Announce Earnings of -$0.38 Per ShareZacks: Analysts Expect Oxford Immunotec Global (OXFD) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - March 30 at 10:02 AM
Oxford Immunotec Global (OXFD) Downgraded to Sell at BidaskClubOxford Immunotec Global (OXFD) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - March 28 at 9:16 PM
Oxford Immunotec Globals (OXFD) Buy Rating Reaffirmed at CowenOxford Immunotec Global's (OXFD) Buy Rating Reaffirmed at Cowen
www.americanbankingnews.com - March 27 at 12:40 AM
Oxford Immunotec Global (OXFD) Upgraded at Zacks Investment ResearchOxford Immunotec Global (OXFD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM
Reviewing Oxford Immunotec Global (OXFD) and Its PeersReviewing Oxford Immunotec Global (OXFD) and Its Peers
www.americanbankingnews.com - March 23 at 12:48 PM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Buy" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 16 at 1:54 AM
Oxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $21.69 MillionOxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $21.69 Million
www.americanbankingnews.com - March 15 at 2:58 PM
Oxford Immunotec Global (OXFD) Upgraded at BidaskClubOxford Immunotec Global (OXFD) Upgraded at BidaskClub
www.americanbankingnews.com - March 14 at 7:12 PM
Oxford Immunotec Global (OXFD) Lowered to Hold at Zacks Investment ResearchOxford Immunotec Global (OXFD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:45 AM
ValuEngine Upgrades Oxford Immunotec Global (OXFD) to "Sell"ValuEngine Upgrades Oxford Immunotec Global (OXFD) to "Sell"
www.americanbankingnews.com - March 11 at 11:13 PM
Zacks Investment Research Upgrades Oxford Immunotec Global (OXFD) to "Buy"Zacks Investment Research Upgrades Oxford Immunotec Global (OXFD) to "Buy"
www.americanbankingnews.com - March 10 at 4:24 PM
Oxford Immunotec to Present at Two Upcoming Investor ConferencesOxford Immunotec to Present at Two Upcoming Investor Conferences
finance.yahoo.com - March 6 at 9:22 AM
Oxford Immunotec Global (OXFD) Downgraded to Strong Sell at ValuEngineOxford Immunotec Global (OXFD) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 1:02 PM
Oxford Immunotec Global (OXFD) Downgraded by BidaskClubOxford Immunotec Global (OXFD) Downgraded by BidaskClub
www.americanbankingnews.com - March 3 at 5:48 PM
Oxford Immunotec Global PLC 2017 Q4 - Results - Earnings Call SlidesOxford Immunotec Global PLC 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 28 at 9:27 AM
Oxford Immunotec Global (OXFD) Releases  Earnings Results, Beats Expectations By $0.03 EPSOxford Immunotec Global (OXFD) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - February 27 at 5:32 PM
Cortina Asset Management LLC Raises Position in Oxford Immunotec Global PLC (OXFD)Cortina Asset Management LLC Raises Position in Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - February 27 at 1:40 PM
Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial ResultsOxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 9:32 AM
Oxford Immunotec Global (OXFD) Upgraded to Hold by BidaskClubOxford Immunotec Global (OXFD) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - February 24 at 10:22 PM
-$0.36 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter-$0.36 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - February 24 at 8:06 AM
Oxford Immunotec Global (OXFD) Scheduled to Post Quarterly Earnings on TuesdayOxford Immunotec Global (OXFD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:46 AM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 19 at 1:46 AM
Insider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of StockInsider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - February 16 at 10:20 PM
Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018
finance.yahoo.com - February 13 at 4:28 PM
BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22
www.reuters.com - February 2 at 9:07 AM
Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from BrokeragesOxford Immunotec Global PLC (OXFD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 25 at 1:30 AM
Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017
finance.yahoo.com - January 8 at 9:17 AM
$25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter$25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - January 6 at 4:14 AM
-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter-$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - January 4 at 1:30 PM
Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare ConferenceOxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:30 AM
Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : January 1, 2018Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : January 1, 2018
finance.yahoo.com - January 1 at 10:03 AM
Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 31 at 1:58 AM
Oxford Immunotec Global Plc is trading above its 50 day moving average : OXFD-US : December 20, 2017Oxford Immunotec Global Plc is trading above its 50 day moving average : OXFD-US : December 20, 2017
finance.yahoo.com - December 20 at 10:16 AM
Oxford Immunotec Global (OXFD) PT Set at $21.00 by BTIG ResearchOxford Immunotec Global (OXFD) PT Set at $21.00 by BTIG Research
www.americanbankingnews.com - December 19 at 10:22 AM

SEC Filings

Oxford Immunotec Global (NASDAQ:OXFD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oxford Immunotec Global (NASDAQ:OXFD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oxford Immunotec Global (NASDAQ OXFD) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.